PMID: 9435921Nov 1, 1994Paper

The impact of indirect costs on outcomes of health care programs

Health Economics
M A Koopmanschap, F F Rutten

Abstract

The impact of including indirect costs of disease (as a result of absence from work, disability and mortality) on outcomes of economic evaluations of specific health care programs is analyzed. For eight health care programs, changes in indirect costs are estimated using the friction cost method, that seeks to estimate the economic losses due to disease or the economic gains of health care programs. The impact of indirect costs on outcomes varies considerably across programs. Indirect costs tend to play an important role if health care programs produce health effects in the short run, if (short term) absence from work is affected considerably and if a significant proportion of the target population is employed at the moment they benefit from the program. The possible induction of treatment related absence from work and disability may also be relevant.

References

Nov 1, 1992·European Heart Journal·J TamargoE Delpón
May 1, 1992·Social Science & Medicine·M A Koopmanschap, B M van Ineveld
Oct 21, 1991·International Journal of Cancer. Journal International Du Cancer·H J de KoningP J van der Maas
Jan 1, 1991·Social Science & Medicine·B Jönsson, P Carlsson
Jan 1, 1990·Social Science & Medicine·M A KoopmanschapJ K Habbema
Jan 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M van BallegooijenH M van Agt
Nov 1, 1988·Southern Medical Journal·F Cushner, R J Friedman
Mar 1, 1981·Social Science & Medicine. Medical Economics·A J Culyer, A K Maynard
Feb 1, 1981·Social Science & Medicine. Part E, Medical Psychology·P Sterling, J Eyer
Mar 1, 1981·Social Science & Medicine. Part F, Medical & Social Ethics·D E Blackman
Apr 1, 1993·Health Economics·K Gerard, G Mooney
Nov 4, 1993·PharmacoEconomics·M A Koopmanschap, F F Rutten

❮ Previous
Next ❯

Citations

Apr 27, 2013·PharmacoEconomics·Marieke KrolFrans Rutten
Jul 22, 1999·Social Science & Medicine·J A Olsen, J Richardson
Jul 18, 2002·Health & Social Care in the Community·Susan MylesRobert G Will
Jun 17, 1999·The New England Journal of Medicine·C P GrossN R Powe
Jun 10, 2004·The Journal of Trauma·Julio López BastidaBeatriz Duque González
May 15, 2007·Journal of Epidemiology and Community Health·Paolo Giorgi RossiUNKNOWN ISDOC Working Group
Jul 9, 1999·Journal of Epidemiology and Community Health·J LordC A Seymour
Oct 16, 2002·American Journal of Respiratory and Critical Care Medicine·Tjard R SchermerConstant P van Schayck
Nov 10, 2001·PharmacoEconomics·J H LoflandK D Frick
Mar 12, 2003·PharmacoEconomics·Jarmo HahlOlli Simell
May 18, 2005·PharmacoEconomics·Jennifer E TranmerPeter C Coyte
May 6, 2005·Treatments in Endocrinology·Carlo LucioniUNKNOWN CODE-2 Italian Advisory Board
Feb 8, 2014·PharmacoEconomics·Marieke Krol, Werner Brouwer
Jun 14, 2013·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Marieke KrolWerner Brouwer
Jan 1, 2009·Journal of Cancer Epidemiology·Isaac E HallCary P Gross
Dec 16, 2000·Clinical Therapeutics·C D MullinsE J Beck
Mar 25, 1999·Clinical Therapeutics·E A Rothermich, D S Pathak
Dec 1, 2003·Expert Review of Pharmacoeconomics & Outcomes Research·Christopher EvansLinda Abetz
Dec 22, 2005·Current Medical Research and Opinion·R GoereeJ-E Tarride
Sep 28, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Clazien BouwmansLeona Hakkaart-van Roijen
Jun 13, 2012·BJU International·Yair LotanMark J C Nuijten
Jul 27, 2010·The Prostate·Ravishankar JayadevappaS Bruce Malkowicz
Jan 30, 2013·Human Vaccines & Immunotherapeutics·Mark JitPhilippe Beutels
Apr 17, 2015·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Marieke KrolLeona Hakkaart
May 6, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·M T HalpernB Geneste
Feb 9, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·L GarattiniC Rossi
Dec 31, 2015·Archives of public health = Archives belges de santé publique·Samuel BosomprahHari Banskota
Jan 22, 2005·Cephalalgia : an International Journal of Headache·S W HamelskyW F Stewart
Oct 5, 2018·American Journal of Industrial Medicine·Martha I Riaño-Casallas, Emile Tompa
Nov 6, 2018·European Journal of Public Health·A FasseehZ Kaló
Mar 25, 2008·Therapeutics and Clinical Risk Management·Giorgio L ColomboGiulio Serra
Jul 2, 1999·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·R GoereeP Goering
Aug 11, 2018·Applied Health Economics and Health Policy·Jamison Pike, Scott D Grosse

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Health Economics
M A KoopmanschapL van Roijen
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
Marieke KrolWerner B F Brouwer
© 2021 Meta ULC. All rights reserved